HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

June 30, 2020

Study Completion Date

January 31, 2024

Conditions
Supratentorial Neoplasms, MalignantMalignant GliomaGlioblastomaAnaplastic AstrocytomaPNETCerebral Primitive Neuroectodermal TumorEmbryonal Tumor
Interventions
BIOLOGICAL

G207

Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI

Trial Locations (2)

35233

Children's of Alabama, Birmingham

43205

Nationwide Children's Hospital, Columbus

Sponsors
All Listed Sponsors
collaborator

Food and Drug Administration (FDA)

FED

collaborator

National Center for Advancing Translational Sciences of the National Institutes of Health

UNKNOWN

collaborator

Cannonball Kids' Cancer Foundation

OTHER

collaborator

Rally Foundation for Childhood Cancer Research

OTHER

collaborator

Hyundai Hope On Wheels

OTHER

collaborator

St. Baldrick's Foundation

OTHER

collaborator

United States Department of Defense

FED

collaborator

The Andrew McDonough B+ Foundation

OTHER

collaborator

Kaul Pediatric Research Institute

UNKNOWN

collaborator

University of Alabama at Birmingham

OTHER

collaborator

Memorial Sloan Kettering Cancer Center

OTHER

collaborator

Kelsie's Crew

UNKNOWN

collaborator

Eli's Block Party Childhood Cancer Foundation

UNKNOWN

collaborator

Eli Jackson Foundation

UNKNOWN

collaborator

Jaxon's F.R.O.G. Foundation

UNKNOWN

collaborator

Battle for a Cure Foundation

UNKNOWN

collaborator

Sandcastle Kids

UNKNOWN

lead

Gregory K. Friedman, MD

OTHER

NCT02457845 - HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors | Biotech Hunter | Biotech Hunter